Generation Bio Inc. (GBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBIO Stock Price Chart Interactive Chart >
GBIO Price/Volume Stats
| Current price | $5.08 | 52-week high | $9.59 |
| Prev. close | $5.00 | 52-week low | $3.40 |
| Day low | $4.71 | Volume | 1,589,600 |
| Day high | $5.19 | Avg. volume | 489,089 |
| 50-day MA | $4.85 | Dividend yield | N/A |
| 200-day MA | $5.54 | Market Cap | 303.10M |
Generation Bio Inc. (GBIO) Company Bio
Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Latest GBIO News From Around the Web
Below are the latest news stories about GENERATION BIO CO that investors may wish to consider to help them evaluate GBIO as an investment opportunity.
Moderna (MRNA) Inks Genetic Medicines Deal With Generation BioModerna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies. |
Moderna, Generation Bio Collaborate To Develop Non-Viral Genetic MedicinesModerna Inc (NASDAQ: MRNA) and Generation Bio Co (NASDAQ: GBIO) have collaborated to combine the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines. "Non-viral DNA therapeutics may offer durable, redosable, titratable genetic medicines to patients suffering from rare and prevalent diseases on a global scale," said Phillip Samayoa, Chief Stra |
UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVIDModerna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio. |
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic MedicinesCollaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio’s ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and develop |
Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic MedicinesCAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines, which will take place virtually on Tuesday, March 28th at 10:00 a.m. ET. About Generation BioGeneration Bio is innova |
GBIO Price Returns
| 1-mo | 26.05% |
| 3-mo | N/A |
| 6-mo | 3.67% |
| 1-year | -24.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 29.26% |
| 2022 | -44.49% |
| 2021 | -75.03% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...